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Selective labeling of cysteine is crucial to enable the study of the many biological processes in which 
cysteine plays a key part in the structure and activity of proteins. In this issue of Chem, Waser, Fierz and 
coworkers describe an efficient, chemoselective cysteine bioconjugation method to introduce 
vinylbenziodoxolone into biomolecules. 
Chemical biologists need tools to precisely engineer proteins so that they can understand and manipulate 
their structure and function.1 The demand for ever better diagnostics and therapeutics has driven the 
development of new chemical methods for single-site attachment of biophysical probes or cytotoxic drugs 
onto proteins.2,3 Initial efforts to selectively label engineered proteins with an non-canonical amino acid or 
peptide fragment revealed the advantages of using precisely modified proteins for biological studies.4,5 
Although these methods require prior sequence manipulation, successful site-selective labeling of 
engineered proteins has encouraged scientists to develop chemical methods for native protein modification. 
In recent years, there have been numerous studies on site-selective labeling of native proteins.6,7  
The challenges for site-selective labeling of engineered proteins of reactivity and selectivity can be 
circumvented through the use of chemoselective transformations — often an orthogonal reaction.4 
However, for native proteins, selective single-site labeling is difficult because of the wide reactivity profile 
resulting from the presence of multiple nucleophilic side-chain amino acids.6,7 Ideally, bioconjugation 
methods should be fast at low protein concentrations, and work at physiological pH and ambient 
temperature. Such reactions should also be able to differentiate one functionality from several nucleophilic 
side-chain residues (chemoselective) and one residue among multiple copies (site-specific). Most 
approaches in native protein modification rely on chemoselective transformations that target the low to 
moderate-frequency residues and the N-terminus -amine. Cysteine residues of both native and engineered 
proteins are ideal targets because they are highly nucleophilic, have relatively low abundance, are easy to 
incorporate into a protein’s sequence, and they react well with a number of readily available chemoselective 
reagents.6,7,8 
α-Halocarbonyl and maleimide derivatives are popular electrophilic reagents for labeling cysteine residues. 
Despite their use in bioconjugation reactions, iodoacetamide derivatives lack chemoselectivity in the 
presence of other nucleophilic amino acids when these reagents are used at high concentrations. The short 
reaction times and high chemoselectivity in reactions between maleimide derivatives with cysteine makes 
them appealing for use in the construction of conjugates for advanced diagnostics and therapeutics.2,3 
However, conjugates formed through maleimide bioconjugation undergo thiol-exchange reactions in the 
presence of external thiols, which leads to loss of label. Reversibility is a serious problem in applications 
that involve antibody-drug conjugates or fluorescence imaging studies because it leads to off-target toxicity 
and non-specific imaging, respectively. Recent approaches for cysteine bioconjugation have sought to 
control reactivity, provide excellent chemoselectivity, be metal-free, and yield sufficiently stable 
conjugates.6,7 
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Figure 1. Bioconjugation of cysteine with EBX. 
In this issue of Chem9, Waser, Fierz and colleagues report a fast, efficient, and highly chemoselective 
approach to give stable cysteine conjugates with ethynylbenziodoxolone (EBX; Figure 1). The resulting 
cysteine conjugate has a vinylbenziodoxolone (VBX) hypervalent iodine bond and an azide group with 
orthogonal reactivity. These reactive handles mean that a tag of interest can be included at a late stage 
through either strain-promoted cycloaddition reaction with the azide or by Suzuki–Miyaura cross-coupling 
reaction with the vinyl hypervalent iodine bond. In this work, the authors used glutathione — a thiol-
containing tripeptide — as a model substrate to optimize the conditions for bioconjugation. Unexpectedly, 
EBX gave cysteine adduct VBX instead of the expected alkynyl sulfide.10 This transformation hinges on 
protonation, rather than α-elimination, followed by S-1,2 shift of the vinylic carbanion intermediate 
generated from the cysteine biomolecule and EBX. Importantly, solvent polarity is key to being able to 
switch between a protonation versus elimination step. The cysteine-EBX conjugate is stable at room 
temperature, at 100 ºC in water, in acidic buffer, and in basic buffer with minimal degradation. The cysteine-
EBX conjugate is also resistant against the thiol-exchange reactions in the presence of external thiol 
nucleophiles, such as tiopronin. 
The reaction works with EBX derivatives that bear a variety of functional groups (azide, alkyne, halide, 
alcohol, and less efficient with lipophilic groups) and small-molecule thiols (thiophenol, benzyl mercaptan, 
cysteine, tiopronin, 6-thioguanine, and thio-β-glucose). EBX exhibits excellent reactivity and high 
chemoselectivity towards cysteine in various natural tetrapeptides and larger peptides (L55-H63 fragment 
of human serum albumin). However, caution needs to be considered when cysteine is present at the C-
terminus as well as next to arginine because of potential oxidation and side products, respectively. Also, 
the method was employed to modify cysteine residues in proteins. Initially, ubiquitin that had an N-terminal 
His-tag followed by a cysteine residue was chosen as a model to test the efficiency of the bioconjugation 
reaction. Two equivalents of EBX resulted in complete conversion to the corresponding ubiquitin-EBX 
conjugate, whereas no labeling occurred with native ubiquitin (lacks a free cysteine), which demonstrates 
the high chemoselectivity of EBX toward cysteine residues. Subsequently, the orthogonality of hypervalent 
iodine reactivity relative to the azide was tested by means of a copper-free strain-promoted azide-alkyne 
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cycloaddition (SPAAC) reaction. This effect was demonstrated on glutathione and ubiquitin by using 
dibenzocyclooctynes with polar groups (acid), affinity tags (biotin), and fluorophores (cyanine dyes). 
Interestingly, the cycloaddition reaction was completely orthogonal to the hypervalent iodine reactivity, 
which opens the possibility to attach yet another tag of interest. 
The bioconjugation conditions can label cysteine residues that result from disulfide reduction in bioactive 
peptides, such as oxytocin and somatostatin. Importantly, the resulting conjugate was stable in the presence 
of a reducing agent. However, the structure of the cyclic peptide was not conserved after labeling, which 
can affect its affinity and function-based applications. Next, the versatility of the method was demonstrated 
by labeling a more complex histone octamer. The mutation of glutamate with cysteine in H4 (E63C) 
followed by assembly with other histones, H2A, H2B, and H3 (C110A) gave the histone octamer complex. 
The cysteine residues were then labeled with EBX and Cy5-DBCO was installed through an azide-
cyclooctyne cycloaddition reaction to give the fluorescently labeled histone octamer complex. The native 
structure of the octamer complex was conserved after labeling, which was demonstrated by continued 
nucleosome formation. The formation of the fluorescently labeled nucleosome was confirmed by native gel 
electrophoresis and fluorescent microscopy analysis. The efficiency of this method for site-specific labeling 
of proteins or more complex systems has yet to be demonstrated, such as with multiple cysteine residues 
present in a protein, therapeutic antibodies or in the presence of other cysteine-containing proteins. 
The stability of hypervalent bond during the azide-cyclooctyne cycloaddition led the authors to investigate 
the dual functionalization of the cysteine-EBX conjugate. To functionalize the hypervalent bond, a Suzuki-
Miyaura cross-coupling reaction was used to give glutathione-EBX and ubiquitin-EBX conjugates without 
degradation of the azide group. Synthesis of a doubly functionalized Cys-labeled ubiquitin was explored 
because of the compatibility of the azide and VBX hypervalent iodine groups together by means of a one-
pot SPAAC-Suzuki-Miyaura reaction. The efficiency the cross-coupling is moderate, but it opens avenues 
for further functionalization of VBX. The authors went on to showcase an application of their method to 
fluorescently label receptors on living cells. The authors functionalized a high-affinity neuropeptide against 
neurokinin-1 receptor that had an additional N-terminal cysteine residue with EBX and then tagged it with 
Cy5-DBCO. The resulting conjugate readily labeled the human embryonic kidney cell line expressing green 
fluorescent protein-tagged NK1 receptor at the cell surface and showed colocalization with the GFP-tagged 
NK1 receptor. Finally, the doubly orthogonal functionalization strategy was applied to improve the 
photostability of the fluorophore through attachment of a fluorescent stain (TSQ) close to the Cy5 dye.  
In summary, this article9 details an efficient protocol to incorporate VBX hypervalent iodine derivatives 
into peptides and proteins through cysteine bioconjugation. VBX and azide are orthogonal in reactivity, 
which enables dual tagging at one site. The high chemoselectivity of cysteine bioconjugation proceeds 
smoothly to give stable conjugates. By understanding of factors that affect the reaction of EBX with 
cysteine and single site-selective labeling of cysteine among multiple copies, applications for cysteine 
labeling in chemical biology and medicinal chemistry can be improved. 
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